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Evaluation of substituted 1,2,3-dithiazoles as inhibitors of the 
Feline Immunodeficiency Virus (FIV) nucleocapsid protein via a 
proposed zinc ejection mechanism 
Christopher R. M. Asquith[a][b], Lidia S. Konstantinova[c][d], Tuomo Laitinen[e], Marina L. Meli[b], Antti 
Poso[e], Oleg A. Rakitin[c][d], Regina Hofmann-Lehmann[b], Stephen T. Hilton[a]* 
Abstract: A diverse library of 5-thieno-, 5-oxo-, 5-imino-1,2,3-
dithiazole derivatives was synthesized and evaluated for  efficacy 
against the Feline Immunodeficiency Virus (FIV) as a model for HIV 
in cells. Several diverse compounds from this series displayed 
nanomolar activity and low toxicity, representing a potential new class 
of compounds for the treatment of FIV and HIV. 
 
Introduction 
 
 
The continual discovery of novel therapeutics against 
varying strains of both viruses and bacteria is essential due to 
their ability to adapt and become resistant to current treatments. 
The human immune deficiency virus (HIV) is a case in point, with 
an array of drugs used to target multiple points in the viral life cycle, 
but the continual development of resistance by the virus has 
continued to erode their efficacy.1 HIV, which results in the 
development of Acquired Immunodeficiency Syndrome (AIDS), 
has caused over 25 million deaths worldwide, with over 34 million 
people currently infected with HIV.2 Amongst non-primate 
lentiviruses such as HIV-1 and HIV-2, only the Feline 
Immunodeficiency Virus (FIV) causes a similar compromised 
immune system as seen in humans,3 with several FIV strains also 
displaying central nervous system involvement and analogous 
AIDS-type disease progression.4,5  
The short basic nucleic acid binding nucleocapsid protein 
(NCp) of HIV and FIV is an under-explored anti-viral target with 
no clinically used drugs, despite its involvement at multiple points 
of the viral replication cycle. These include annealing of the 
cellular primer tRNA3lys to the primer binding site in reverse 
transcrption,6,7 promotion of dimerisation, packing and 
organization of protein-RNA complexes within freshly created 
virons.8-10 The NCp is an attractive protein target as it has been 
shown to be mutation resistant with inhibition yielding non-
infectious virons.6,11 It contains a conserved double zinc finger 
peptide unit C-X2-C-X4-H-X4-C (CCHC) that is found in nearly all 
retroviruses with the exemption of spumaviruses,7 including HIV-
1/2,12,13 FIV,14 Simian Immunodeficiency Virus (SIV),15 Equine 
Infectious Anemia Virus (EIAV)16 amongst others.17 The 
development of an effective agent that could target one or both of 
these zinc fingers of the nucleocapsid protein would render the 
virus inert as deletion or modification of either zinc finger leads to 
virus inactivation.18,19 
Two different approaches have been utilised towards the 
development of nucleocapsid inhibitors; the first, based on small 
molecules that compete with the binding of the substrate RNA 
nucleic acid chain has met with some success.20,21 The second 
approachis based on the irreversible ejection of the structural Zn2+ 
ion has been more productive. Key compounds with this 
mechanism of action are exemplified by compounds 1-8.22-29 
Common functionalities include a disulphide bridge and more 
recently a diselenide bridge30 and/or a stable electronically 
deficient core/functional group(s) (Figure 1).  
 
 
Figure 1. Previously reported zinc abstractors in the literature 
 
As part of a longer term program focusing on the 
development of novel anti FIV/HIV agents that target the NCp via 
zinc abstraction, exploring the development of novel compound 
classes. We achieved this using FIV as a surrogate model for HIV; 
the results of our investigations are reported below. 
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Results and Discussion 
 
In order to develop novel therapeutic agents against the NCp of 
FIV, we used an in silico homology model derived from HIV-1 and 
EIAV nucleocapsid proteins to explore heteroatom rich disulphide 
containing compounds. Building on our previous knowledge 
relating to bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole 
derivatives31 and tetrathiocine derivatives32. The 1,2,3-diathiazole 
core caught our interest as it has been shown to have a broad 
biological inhibition profile with activities. These properties include 
anti-bacterial,33-35 anti-cancer,37-38 anti-fungal/herbicidal39-43 and 
anti-melanin activities.44 
The 1,2,3-dithiazole scaffold is a stable and has the 
potential to be substituted at the C-4 and C-5 positions, while 
containing an electrophilic disulphide bond. Substitutions were 
made to explore the propensity of the disulphide to react with the 
cysteine thiolates of the NCp model. Investigation of the alignment 
and electronic distribution of the 1,2,3-dithiazole core led to a 
small selection of structurally diverse compounds, which were 
computationally modelled using Density Functional Theory (DFT) 
and a small selection of compounds were then synthesized and 
tested (Figure 2).  
 
 
 
 
Figure 2. Virtual screening was based on both molecular docking (left) and DFT 
molecular orbital calculations (right). Molecular docking was used to estimate if 
the screened compound is able to achieve a suitable docking pose. The DFT 
calculations were based on the docking poses and thus validated if the frontier 
orbitals of the reactants are geometrically optimally located or not (HOMO 
orbitals marked using a red surface and the LUMO-orbitals of blue colored 1,2,3 
dithiazole scaffold), (Schrödinger Maestro). 
 
A series of selected 1,2,3-dithiazoles containing a 
disulphide bridge and our supporting mechanistic rationale 
demonstrating the potential of this heterocyclic system. These 
heterocycles pose under-reported in the literature, due to the fact 
that C-5 substituted derivatives are a relative synthetic 
challenge.45 
To date, 1,2,3-dithiazole chemistry has centered around the 
4,5-dichloro-1,2,3-dithiazolium chloride salt (Appel Salt) and the 
susceptibility of attack by nucleophiles at the S-1, S-2, C-4 and C-
5 atoms.46 We anticipated that these synthetic mechanisms to 
access the core could also potentially play a part in the zinc 
abstraction mechanism.47 Although a C-5 chloride substitution is 
more commonly reported with the Appel salt chemistry, this could 
present an issue relating to the ability of the chloride to act as a 
potential leaving group in the final compound.  
The synthesis of novel 4- and 5-substituted-1,2,3-
dithiazoles bearing a thioketone, oxo, imino or ethyl 2-cyano-2-
acetate ylidene functionality at C-5 position were performed 
utilising the reaction between substituted ethanoneoximes and 
sulphur monochloride according to a one-pot protocol generating 
an in-situ pre-functionalised dithiazolium salt intermediate before 
treatment with a selected nucleophile (Scheme 1).48,37 
 
 
Scheme 1. Synthesis of dithiazole derivatives - Reagents and Conditions - (a) 
S2Cl2/Pyridine, CH3CN, Ar, -5 to 0 oC, 15 mins; (b) thioacetamide, 0 to 25 oC, 
CH3CN, Ar, 2 hr; (c) formic acid, CH3CN, Ar, 0 oC at 30 mins, 1 hr at reflux; (d) 
ethyl 2-cyanoacetate, pyridine, 25 oC, CH2Cl2, 5 hr; (e) aniline/benzyl amine, 
CH3CN, Ar, 0 oC at 30 mins, followed by pyridine. 
 
The ethanoneoximes 9a-g were prepared according to 
literature procedures in quantitative yields by heating a mixture of 
the corresponding ketones or aldehydes with an excess of 
hydroxylamine hydrochloride with sodium acetate in methanol at 
reflux.49 The oximes were subsequently suspended in acetonitrile 
and reacted with disulphur dichloride, with pyridine added 
dropwise to form the related dithiazolium salt intermediate, which 
was then treated with the appropriate nucleophilic source. 
A number of methods exist for the formation of 4-chloro-1,2,3-
dithiazolo-5-thione, including the use of hydrogen sulphide in 
acetonitrile46 or 2-cyanothioacetamide,50 but we chose to utilise 
thioacetamide for its ease of use and low cost. Thioacetamide 
was added after preparation of the dithiazole salt derivative and 
this selectively gave compounds 10a-e in good yields. 5-
Oxodithiazoles were synthesised by replacing thioacetamide with 
formic acid, to produce 11a-c. 5-Iminodithiazoles were prepared 
in a similar fashion by substituting thioacetamide with aniline to 
give 12a-d. Compound 13 was produced by treatment of the 9a 
dithiazole salt derivative with ethyl cyanoacetate, although the 
modelling indicated that this compound was not optimal, we 
wanted to investigate if having a polar head group such as this 
cyano ester derivative would be tolerated. 
Compounds 10-13 were then screened for toxicity in-vitro 
against feline kidney cells and tested for anti-viral efficacy in- vitro 
against a chronically infected feline lymphoid cell line. 
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Table 1. Results from the 1,2,3-dithiazole scaffold FIV screening 
 
[a] Sample concentration of 10 μM of compound on CrFK cells for 24 hours - 
percentage viability; [b] Geometric mean, each concentration tested in triplicate 
after 7 days as a difference of a untreated DMSO control FL-4 cells with a less 
than 10% error; [c] Therapeutic index is CC50/EC50, which is the ratio of toxicity 
to activity; [d] Calculated using ChemBioDraw Ultra 14. 
 
Biological testing of the compounds was based on dual 
approach, the first aimed to identify any compounds with non-
specific toxicity at three higher concentrations (1 μM - 100 μM) in 
a short MMT cell viability assay51 over 24 hours exposing Crandell 
Rees Feline Kidney cells (CrFK).52 The second provided an 
enhanced longer-term cytotoxicity screen and an anti-FIV profile 
at six concentrations (1 nM to 100 μM) over seven days, using an 
IL-2 independent feline lymphoblastoid cell line (FL-4).53 FL-4 
cells infected with FIV were exposed to the compounds over a 
period of seven days and sampled every day and at each of six 
concentrations; to determine the extent of viral 
replication/suppression. Viral RNA was isolated from cell culture 
supernatants using the MagNA Pure LC System by the Total 
Nucleic Acid Isolation Kit (Roche Applied Science). Viral loads 
were determined by quantitative real-time reverse transcription 
polymerase chain reaction (RT-qPCR).54 The remaining cells 
were subjected to a MTT cell viability assay to rule out any toxicity 
effects and validate that the RT- qPCR result is not 
 
 
 
 
 
 
 
caused by non-specific toxicity and provide a therapeutic index for 
each compound.  
The results obtained demonstrated that activity was 
observed at varying potencies across each series with nanomolar 
activities as seen with 10a (Table 1). Toxicity was generally light 
when observed in the initial screening with CrFK cells with 24-
hours exposure. This is generally a good indication of the level of 
toxicity that would be observed if there was a clearance 
mechanism in the FL-4 assay. There appears to be a roughly ten-
fold increase in toxicity when looking at the results for the FL-4 
assay relative to the CrFK data, but this has to be taken in the 
context of chronic exposure in an in-vitro assay and would not 
necessarily be truly representative of an in-vivo system. 
Importantly, the overall results show that even with prolonged 
exposure to these potentially zinc abstracting agents there is a 
good therapeutic index, which suggests that zinc abstraction is 
not intrinsically tied to cytotoxicity. The toxicity does not show any 
correlation with the activity displayed by the most active 
compounds such as 10a and 11b. While 12a also displays good 
activity and represents an improvement on previous work within 
our group, the therapeutic index (CC50/EC50) still requires further 
improvement.  
After the initial promising result with 10a we looked to 
expand a small cluster of compounds around the main scaffold 
and alter structural features of the core compound to increase the 
Number X R CrFKa CC50b EC50b TI c cLogP d 
      (%) (µM) (µM)     
10a S Phenyl >100 >100 0.023 >4000 3.53 
10b S 4-Methoxyphenyl  96.43 39.24 0.456 86.1 3.45 
10c S 4-Fluorophenyl >100 42.17 2.66 15.8 3.67 
10d S 2-Benzofuranyl 74.1 3.04 0.9044 6.7 4.3 
10e S 2-Thiophenyl 57.2 6.02 0.1773 17.1 3.38 
11a O 4-Methoxyphenyl  >100 40.84 0.193 211.6 2.16 
11b O 4-Fluorophenyl >100 63.52 0.025 >2500 2.38 
11c O 4-Nitrophenyl 87.45 6.26 0.4325 14.5 1.98 
12a N-Ph Phenyl 75.66 7.49 0.5888 12.7 5.84 
12b N-Ph 4-Methoxyphenyl  66.78 4.53 0.1398 32.4 5.76 
12c N-Ph 4-Nitrophenyl 92.51 9.74 0.5001 19.5 5.58 
12d N-Ph Ethyl ester 76.64 28.21 0.0665 424.2 4.24 
13 
 
4-Fluorophenyl 90.33 3.24 0.2397 13.5 3.36 
14 S Phenyl 71.11 0.681 0.392 1.7 4.79 
15 - AZT >100 >100 5.31 18.8 -0.16 
16 - raltegravir >100 >100 0.01 >10000 1.16 
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therapeutic index. However, with 10b-e, we found there to be a 
drop off in activity when compared to 10a, with 10d and 10e 
showing unfavorable therapeutic indexes when compared to 10a, 
combined with lower overall activity. The slightly increased EC50 
of 10c could be due to limited cell penetration compared to the 
other counterparts or the fact that sulphur is less electronegative 
relative to oxygen.55 This drop in activity was not observed with 
the switch to the oxygen analogue 11b which was almost as 
potent as 10a, but in displaying increased toxicity, the 
corresponding therapeutic index was lower. We expected a boost 
from a nitro group substitution (11c and 12c) but this modification 
led to an increase in toxicity with no material potency gain. The 
consistent substituent across each series was the para-
methoxyphenyl group, which was used to screen the ` head group`. 
Whilst the results of these compounds were quite consistent, they 
did not demonstrate improved potency but displayed increased 
toxicity when compared with 10a in this in-vitro system. 
Interestingly an increase in cLogP beyond 5 did not significantly 
inhibit the activity or affect the solubility of compounds 12a-c. 12d 
and 13 were investigated to understand if disruption to the core 
structure via removal of sulphur or oxygen would be tolerated and 
whilst activity was observed, there was not a significant 
improvement over 10a, due to an increased metabolic liability 
from the ethyl ester. The activity of azidothymidine (AZT) - 15 and 
raltegravir - 16 are consistent with previous reports in FIV/HIV.56,57 
The focus of this work builds on the idea that the disulphide 
bridge is pivotal to the activity of the compounds against the NCp 
target, we also aimed to demonstrate that the disulphide is 
essential for activity by synthesizing a disrupted 1,2,3-dithiazole 
system with a disulphide bond by treatment of 10a with 
benzylamine (Scheme 2),58,59 to give 1,2,5-thiadiazolothione 14. 
However, we found the utility of this compound to be limited by 
toxicity, after prolonged cellular exposure. The EC50 closely 
mapped to the CC50 with a resulting therapeutic index of less than 
2, this meant that this was not a definitive way to demonstrate if 
the disulphide bridge was essential or not. This observation 
may/may not support our hypothesis that the disulphide bridge 
was essential for the activity observed, but was not conclusive. 
 
 
 
 
 
 
Scheme 2. Reaction of 5H-1,2,3-dithiazole-5-thiones 10a to form 14 - Reagents 
and Conditions - (a) benzyl amine, THF, Ar, 3 hr, r.t. 
 
With the activities observed our proposed mechanism of 
action of this class of compound involves modification of the zinc-
binding sites on the NCp of FIV which we determined using DFT 
calculations. Support for this idea comes from previous NMR and 
MS studies on HIV NCp7 that have shown observable formation 
of protein-zinc-thiol(ate) complexes and covalent modifcations.25 
We reasoned that 1,2,3-dithiazole mediated zinc ion abstraction 
ejection also occurs via an analogous mechanism to known zinc 
binding/disrupting compounds in which a zinc-binding cysteinyl 
thiol(ate) reacts with the disulphide of the core to generate a 
transient protein-DTA disulphide (Figure 3).25,36,60 This can then 
rearrange to form an intramolecular protein disulphide with 
consequent reduction in zinc ion affinity. The ejected zinc ion (or 
zinc 1,2,3-dithiazole complex) could then potentially complex with 
a second (reduced) 1,2,3-dithiazole core to form a stable complex 
which is analogous to work previously reported on the 
epidithiodiketopiperazine class of natural products.60-62  
 
Figure 3. Proposed mechanism of action of 1,2,3-dithiazole for modification of 
NCp homology model. A - summary of the mechanism of zinc ejection from 
NCp/NCp7. B - a Zn2+-coordinating cysteine thiol(ate) reacts with the disulphide 
of the 1,2,3-dithiazole core to generate a transient intermediate disulphide. The 
disulphide then rearranges to form an intramolecular protein disulphide with 
consequent reduction in zinc ion affinity. The ejected zinc ion (or part Zn2+ 
complex) can then complex with a second 1,2,3-dithiazole core (reduced) to 
form a stable complex. 
 
Observations from our calculations show that it is unlikely 
that thermodynamic parameters drive the observed kinetics. 
Once disulphide exchange occurs between the zinc finger and the 
inhibitor, the zinc finger in the protein is no longer able to re-form 
and equilibrium to regenerate the structure is unable to be 
established. We therefore propose this mechanism using a kinetic 
argument whereby the energy barrier for zinc ejection is favored 
and in addition that the formation of a stable zinc complex is 
potentially thermodynamically favored. When the requisite 
disulphide bridge in the inhibitor is interrupted in compound 14, 
this disruption to the zinc finger can no longer occur and 
abstraction of zinc by our proposed mechanism is not available to 
this compound leading to the observed limited activity (Figure 4). 
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Figure 4. Global reactivity was estimated by calculation of the Fukui frontier 
molecular orbitals of 10-14 respectively and the propensity of the protein to 
undergo zinc abstraction. Fukui f+ negative visualized using iso-values 0.0015 
(white) and 0.005 (green), (Schrödinger Maestro). 
 
Conclusions 
 
The sub-micromolar potencies of the compounds described 
in this study combined with the lower toxicities show a step 
change in progression towards the development of useful 
candidate compound for the targeting of the FIV/HIV 
nucleocapsid protein. The low toxicity and high activity of the initial 
hit 10a led us to believe that improved compounds with enhanced 
characteristics were possible. Many avenues of development 
exist such as a substitution at the para position of the pendant 
phenyl ring to prevent P450 metabolism while still maintaining 
activity. We demonstrated that 10a struck a good overall balance 
between activity and toxicity. With the quantum calculations 
demonstrating the viability of zinc ejection, this opens up the 
possibility of our investigations with the aim of generating lead 
structures with more favorable profiles. While we have enhanced 
the repertoire of the 5-thieno, 5-oxo, 5-imino-1,2,3-dithiazole 
class of compounds, the hope is that this work will allow us to 
generate a pre-clinical candidate that can treat both FIV and HIV 
in an in-vivo setting and this will be reported in due course. 
 
Experimental Section  
 
Modelling Calculations 
 
Molecular Docking  
 
A quantum polarized molecular docking study for a number of 
compounds (Figure 2) was conducted, which was similar to that 
previously generated using a homology model,31 with the version 
used in this study based on HIV-1 PDB:2JZW (NCp7)63 and EIAV 
PDB:2BL6 (NCp11) as a model for the FIV NCp.16 The inhibitory 
mechanism of compounds is assumed to begin with coordination 
of compounds against more the accessible zinc finger motif of the 
model (Figure 3). Our previous homology modelling and docking 
studies suggest that inhibitory activity can be partly explained by 
means of facile coordination of compounds close to the more 
accessible zinc finger structure. 
DFT Molecular Orbital Calculations. 
 
The zinc finger structure is not well described by means of 
molecular mechanics based molecular docking; hence we used 
Jaguar DFT calculations for docking pose derived model. The 
geometry of zinc finger cysteines and histidines were constrained 
to their initial geometry using Cartesian constraints to connector 
carbon atoms. B3LYP of theory and MSV basis set were used for 
geometry optimizations in the gas phase. Reactivity of selected 
compounds were separately estimated by unconstrained gas 
phase geometry optimizations (B3LYP/6-31g**) followed by 
single point Fukui frontier molecular orbital calculations 
(visualised in Figure 4), (Schrödinger Inc., New York, NY, USA). 
 
Biology 
 
Initial Short Cytotoxicity Assay.  
 
Crandell Reese feline kidney (CrFK) cells52 were cultured in 96-
well plates (TPP, Trasadingen, Switzerland) at a density of 10,000 
cells/well, in complete medium (RPMI 1640 medium (Sigma-
Aldrich, Buchs, Switzerland), containing 10% Fetal Calf Serum 
(FCS) 100 M/mL Glutamine and 1% v/v antibiotic/antimycotic 
(Ab/Am) (all three, Gibco Life Technologies, Zug, Switzerland)). 
The antiviral compounds were dissolved in 2% DMSO (Sigma-
Aldrich, Buchs, Switzerland) to make a 1M stock solution. The 
compounds were 10-fold serially diluted with complete medium. 
Six dilutions of the compounds (100 µM to 1 nM) were added in 
triplicate on the CrFK cells (200 µL) and incubated for 24 hours 
(37 oC, 5% CO2). The medium was removed and replaced with 
phenol red free medium and (180 µL) and 
methylthiazolyldiphenyl-tetrazolium bromide (MTT) (4 mg/mL) 
(Sigma-Aldrich, Buchs, Switzerland) (20 µL) incubated for 4 
hours. The medium was removed by vacuum and the cells were 
lysed with methanol (200 µL) to reveal a bright purple formazan 
product.51 The methanol-formazan absorbance was determined 
at 570 nm (BioTek Synergy HT plate reader with KC4 software, 
Cambridge systems) values expressed as a 50% cytotoxic 
concentration (CC50). 
 
FIV Viral Loading Studies.  
 
The potential antiviral effect against FIV was tested in a cell 
culture assay using an IL-2 independent feline FL-4 feline 
lymphoblastoid cell line.53 The compounds were added as 
concentrations ranges in triplicate as above. The cell supernatant 
(100 µL) was removed, frozen at -20 °C and replaced daily for 7 
days. To determine the “long-term” cytotoxicity, on Day 7 the cell 
culture supernatant was replaced with phenol red free medium 
(80 µL) and the cells were subjected to the MTT assay (as before). 
The day 7 cell culture supernatants were centrifuged in a table-
top centrifuge (10000 x g) maximal speed for 2 min to pellet cells 
and debris. Cell culture supernatant of each triplicate were pooled 
and frozen immediately at -20 ºC until analysis. Total nucleic acids 
(TNA) were extracted using the MagnaPure LC TNA extraction kit 
(Roche, Basel, Switzerland) from 100 µL of pooled according to 
manufacturer's instructions. FIV RNA was quantitated by RT-
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qPCR as described for FIV, using DSMO and untreated cells as 
controls.54 Results were expressed as 50% effective 
concentrations (EC50) determined by a sigmoid dose-response 
curve at 50% inhibition determined by sigmoid dose-response 
curve fitting using GraphPad Prism version 6.0 (GraphPad Inc., 
La Jolla, CA, USA) and an RNA standard.  
 
Chemistry 
General - Melting points were determined on a Kofler hot-stage 
apparatus and are uncorrected. IR spectra were recorded on a 
Specord M-80 instrument in KBr pellets. 1H NMR were recorded 
on a Bruker WM 300 spectrometer (300 MHz) and 13C NMR 
spectra were recorded on a Bruker AM 300 (75.5 MHz) in CDCl3. 
J values are given in hertz. Mass spectra were recorded on a 
Finnigan MAT INCOS 50 instrument using electron impact 
ionization. Elemental analyses were performed on Perkin Elmer 
2400 Elemental Analyser. 
General Procedure A: 4-Phenyl-5H-1,2,3-dithiazole-5-thione 
(10a): Pyridine (0.243 mL, 3.0 mmol) was added dropwise at −5 
to 0 °C to a stirred solution of (E)-1-phenylethan-1-one oxime 9a47 
(135 mg, 1.0 mmol) and sulphur monochloride (0.160 mL, 
2.0 mmol) in acetonitrile (10 mL) under an inert atmosphere of 
argon. The mixture was stirred at 0 °C for 15 min and 
thioacetamide (83 mg, 1.1 mmol) added in one portion and the 
resulting mixture stirred at r.t. for 2 h, filtered and solvents 
evaporated under reduced pressure. The residue was purified by 
column chromatography (Silica gel Merck 60, light petroleum and 
then light petroleum-CH2Cl2 mixtures) to afford compound 10a as 
a brown solid (155 mg, 73%): m.p. 95-100 °C. Anal. Calcd for 
C8H5NS3 (%): C, 45.47; H, 2.39; N, 6.63. Found (%): C, 45.55; H, 
2.43; N, 6.70. 1H NMR (300 MHz, CDCl3) δ: 7.36 (3H, m, Ph), 7.47 
(2Н, m, Ph). 13C NMR (75.5 MHz, CDCl3) δ: 128.0, (2 CH, Ph), 
129.4 (2 CH, Ph), 130.5 (CH, Ph), 131.3, 179.3 (2 sp2 tertiary C), 
208.0 (С=S). MS (EI, 70 eV), m/z (%): 211 (M+, 100), 135 (95), 
103 (30). IR (KBr), ν/cm-1: 3056, 2920 (С-Н), 2852, 2356, 2336, 
1436, 1132 (С=S), 604, 499 (S-S).37 
 
4-(4-Methoxyphenyl)-5H-1,2,3-dithiazole-5-thione (10b): (E)-
1-(4-Methoxyphenyl)ethan-1-one oxime 9b47 (165 mg, 1 mmol) 
was treated according to general procedure A to afford compound 
10b as pale brown crystals (73 mg, 30%): m.p. 68-71 °C. Anal. 
Calcd. for C9H7NOS3 (%):C, 44.79; H, 2.92; N, 5.80; O, 6.63. 
Found (%): C, 44.95; H, 3.08; N, 6.04. 1H NMR (300 MHz, CDCl3), 
δ: 3.87 (3H, s, CH3); 6.98 (2H, d, 2 CH, J = 8.8 Hz), 8.98 (2H, d, 
2 CH, J = 8.8 Hz). 13C NMR (75.5 MHz, CDCl3) δ: 55.4 (CH3), 
113.5 (2 CH, Ar), 123.9 (2 CH, Ar), 131.1, 161.4, 167.3 (3 Cquat), 
208.4 (C=S). MS (EI, 70 eV), m/z (%): 241 (M+, 28), 210 (15), 197 
(4), 133 (100). IR (KBr), ν/cm-1: 2924 (С-Н), 2852, 1600, 1516, 
1280, 1144, 1036, 828, 752, 700.48 
 
4-(4-Fluorophenyl)-5H-1,2,3-dithiazole-5-thione (10c): (E)-1-
(4-Fluorophenyl)ethan-1-one oxime 9c47 (153 mg, 1 mmol) was 
treated according to general procedure A to afford compound 10c 
as brown crystals (92 mg, 40%): m.p. 148-152 °C. Anal. Calcd for 
C8H4FNS3 (%): C, 41.90; H, 1.76; N, 6.11. Found (%): C, 41.83; 
H,1.89; F, 8.29; N, 6.11. 1H NMR (300 MHz, CDCl3) δ: 7.15 (2Н, 
t, J = 8.80, Ar), 7,98 (2Н, m, Ar). 13C NMR (75.5 MHz, CDCl3) δ: 
115.4, 130.2 (sp2 tertiary C), 131.7 (4 CH, Ar), 150.9, 140.6, 165.7 
(3 sp2 tertiary C), 208.0 (С=S). MS (EI, 70 eV), m/z (%): 229 (M+, 
78), 209 (10), 185(12), 153 (89). IR (KBr), ν/cm-1: 2924 (С-Н), 
2856, 1888, 1600, 1508, 1408, 1272, 1136, 852, 792, 680.37 
 
4-(1-Benzofuran-2-yl)-5H-1,2,3-dithiazole-5-thione (10d): (E)-
1-(Benzofuran-2-yl)ethan-1-one oxime 9d47 (175 mg, 1 mmol) 
was treated according to general procedure A to afford compound 
10d as red crystals (138 mg, 55%): m.p. 132-134 °C. Anal. Calcd 
for C10H5NOS3 (%): C 47.79; H, 2.01; N, 5.57; O, 6.37. Found (%): 
C, 47.92; H, 2.23; N, 6.76. 1H NMR (300 MHz, CDCl3) δ: 7.32 (1H, 
m, Bzf), 7.44 (1H, m, Bzf), 7.62 (1H, d, J = 8.1, Bzf), 7.73 (1H, d, 
J = 7.3, Bzf), 8.50 (1H, s, Bzf). 13C NMR (75.5 MHz, CDCl3) δ: 
110.7, 111.4, 122.9, 123.6, 127.1 (5 CH, Bzf), 132.9, 140.8, 147.6, 
168.7 (4 sp2 tertiary C), 205.2 (C=S). MS (EI, 70 eV), m/z (%): 251 
(M+, 23), 175 (59), 143 (58). IR (KBr), ν/cm-1: 1648, 1612, 1560, 
1348, 1260, 1164, 1036, 828, 748, 700.37 
 
4-Thien-2-yl-5H-1,2,3-dithiazole-5-thione (10e): (E)-1-
(Thiophen-2-yl)ethan-1-one oxime 9e63 (141 mg, 1 mmol) was 
treated according to general procedure A to afford compound 10e 
as red crystals (54 mg, 25%): m.p. 89-92 °C. Anal. Calcd for 
C6H3NS4 (%).C, 33.16; H, 1.39; N, 6.44. Found (%): C, 33.28; H, 
1.54; N, 6.14. HRMS Anal. Calcd for C6H3NS4: 216.9148, Found: 
216.9151. 1H NMR (300 MHz, CDCl3) δ: 7.14 (1Н, m, Th), 7.53 
(1Н, d, J = 5.1 Hz, Th), 8.36 (1Н, d, J = 4.4 Hz, Th). 13C NMR 
(75.5 MHz, CDCl3) δ: 127.2, 130.7, 131.7 (3 CH, Th), 133.9, 164.0 
(2 sp2 tertiary C), 205.6 (C=S). MS (EI, 70 eV), m/z (%): 217 (M+, 
73), 141 (100), 109 (53). IR (KBr), ν/cm-1: 3100, 2920 (С-Н), 2852, 
1520, 1412, 1364, 1276, 1140, 984, 824, 784.37 
 
General Procedure B: 4-(4-Methoxyphenyl)-5H-1,2,3-
dithiazole-5-one (11a): Pyridine (0.243 mL, 3 mmol) was added 
dropwise at −5 to 0 °C to a stirred solution of (E)-1-(4-
methoxyphenyl)ethan-1-one oxime 9f47 (165 mg, 1 mmol) and 
sulphur monochloride (0.160 mL, 2 mmol) in acetonitrile (10 mL) 
under argon. The mixture was stirred at 0 °C for 15 min followed 
by addition of formic acid (0.189 mL, 5 mmol) and the resulting 
mixture was stirred at 0 °C for 30 min and heated at reflux for 1 h, 
filtered and solvent were evaporated under reduced pressure. 
The residue was purified by column chromatography (Silica gel 
Merck 60, light petroleum and then light petroleum–CH2Cl2 
mixtures) to afford compound 11a as yellow crystals (146 mg, 
65%): m.p. 59-62 °C. Anal. Calcd. for C9H7NO2S2 (%):C, 47.98; H, 
3.13; N, 6.22; O, 14.20. Found (%): C, 48.12; H, 3.31; N, 6.48. 1H 
NMR (300 MHz, CDCl3) δ: 3.87 (3Н, s, CH3) 6.97 (2Н, d, J = 8.8 
Hz, Ar), 8.15 (2Н, d, J = 9.5 Hz, Ar). 13C NMR (75.5 MHz, CDCl3) 
δ: 55.5 (СH3), 114.1 (2 СН, Ar), 129.6 (2 CH, Ar), 123.8, 154.4, 
161.8 (3 sp2 C), 190.5 (С=O). MS (EI, 70 eV), m/z (%): 225 (M+, 
27), 197 (7), 165 (5), 133 (100). IR (KBr), ν/cm-1: 3064 (С-H), 3008, 
2920, 2840, 1656 (С=О), 1576, 1508, 1248, 1180, 832, 684.59  
 
4-(4-Fluorophenyl)-5H-1,2,3-dithiazole-5-one (11b): (E)-1-(4-
Fluorophenyl)ethan-1-one oxime 9c47 (153 mg, 1 mmol) was 
treated according to general procedure B to afford compound 11b 
as yellow crystals (107 mg, 50%): m.p. 70-72 °C. Anal. Calcd. for 
C8H4FNOS2 (%): C, 45.06; H, 1.89; F, 8.91; N, 6.57; O, 7.50. 
Found (%): C, 44.89; H, 1.98; N, 6.37. 1H NMR (300 MHz, CDCl3) 
δ: 7.15 (2Н, t, J = 8.5, Ar), 8.19 (2Н, t, J = 8.5, Ar). 13C NMR (75.5 
MHz, CDCl3) δ: 115.8 (2 CH, d,  J = 23.0 Hz, Ar), 130.1 (2 CH, d, 
J = 7.0 Hz, Ar), 127.1, 153.8, 164.3 (C-F, s, J = 251.0 Hz), (3 sp2 
C), 190.1 (С=O). MS (EI, 70 eV), m/z (%): 213 (M+, 14), 185 (14), 
121 (40). IR (KBr), ν/cm-1: 3072 (С-Н), 1920, 1676 (С=О), 1596, 
1512, 1408, 1272, 1164, 804, 696.59  
 
4-(4-Nitrophenyl)-5H-1,2,3-dithiazole-5-one (11c): (E)-1-(4-
Nitrophenyl)ethan-1-one oxime 9f47 (153 mg, 1 mmol) was treated 
according to general procedure B to afford compound 10c as 
yellow crystals (84 mg, 35%): m.p. 155-156 °C. Anal. Calcd. for 
C8H4N2O3S2 (%): C, 39.99; H, 1.68; N, 11.66. Found (%): C, 
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40.31; H, 1.81; N, 11.62; O, 19.98; S, 26.69. 1H NMR (300 MHz, 
CDCl3) δ: 8.33 (2Н, d, J = 8.8 Hz, Ar), 8.40 (2Н, d, J = 8.8 Hz, Ar). 
13C NMR (75.5 MHz, CDCl3) δ: 129.0 (2 CH, Ar), 133.9 (2 CH, Ar), 
141.7, 153.4, 158.7 (3 sp2 C), 195.5 (С=O). MS (EI, 70 eV), m/z 
(%): 240 (M+, 5). IR (KBr), ν/cm-1: 3100 (С-H), 1667 (С=О), 1652, 
1600, 1512, 1408, 1348, 1300, 1272, 860, 796, 672.59  
 
General Procedure C: N-[(5Z)-4-Phenyl-5H-1,2,3-dithiazol-5-
ylidene]aniline (12a): Pyridine (0.243 mL, 3 mmol) was added 
dropwise at −5 to 0 °C to a stirred solution of (E)-1-phenylethan-
1-one oxime 9a47 (135 mg, 1 mmol)  and sulphur monochloride 
(0.160 mL, 2 mmol) in acetonitrile (10 mL) under an inert 
atmosphere of argon. The mixture was stirred at 0 °C for 15 min, 
whereupon aniline (1 mmol) was added and the mixture stirred at 
0 °C for 30 min, followed by addition of pyridine (0.162 mL, 2 
mmol). The reaction mixture was filtered and solvents were 
evaporated under reduced pressure. The residue was purified by 
column chromatography (Silica gel Merck 60, light petroleum and 
then light petroleum-CH2Cl2 mixtures) to afford compound 12a as 
bright yellow crystals (149 mg, 55%): m.p. 73-76 °C. Anal. Calcd. 
for C14H10N2S2 (%): C, 62.19; H, 3.73; N, 10.36. Found (%): C, 
62.25; H, 3.68; N, 10.62. 1H NMR (300 MHz, CDCl3) δ: 7.19 (3H, 
m, Ph), 7.48 (5Н, m, Ph), 8.22 (2Н, m, Ph). 13C NMR (75.5 MHz, 
CDCl3) δ: 119.0, 125.6, 128.1, 129.0, 129.8, 130.3 (10 CH, Ar), 
132.6, 153.1, 159.2, 165.4 (4 sp2 tertiary C). MS (EI, 70 eV), m/z 
(%): 270 (M+, 96). IR (KBr), ν/cm-1: 3048 (С-Н), 1604, 1598, 1500 
(С=N), 1280, 633, 488 (S-S).37 
 
N-[(5Z)-4-(4-Methoxyphenyl)-5H-1,2,3-dithiazol-5-ylidene]-N-
phenylamine (12b): (E)-1-(4-Methoxyphenyl)ethan-1-one oxime 
9b64 (135 mg, 1 mmol) was treated according to general 
procedure C to afford compound 12b as yellow crystals (81 mg, 
27%): m.p. 84-85 °C. Anal. Calcd. for C15H12N2OS2 (%):C, 59.98; 
H, 4.03; N, 9.33; O, 5.33. Found (%): C, 60.21; H, 4.22; N, 9.32. 
1H NMR (300 MHz, CDCl3) δ: 3.88 (3Н, s, CH3), 6.98 (2Н, d, J = 
9.5 Hz, Ar), 7.20 (3Н, m, Ar), 7.46 (2Н, d, J = 8.8 Hz, Ar), 8.25 
(2Н, d, J = 8.8 Hz, Ar). 13C NMR (75.5 MHz, CDCl3) δ: 55.3 (СH3), 
113.5 (2 CH, Ar), 119.0 (2 CH, Ar), 129.8 (2 CH, Ar), 130.6 (2 CH, 
Ar), 125.3 (CH, Ar); 125.6, 153.1, 158.4, 161.2, 165.8 (5 sp2 C). 
MS (EI, 70 eV), m/z (%): 300 (M+, 25), 167 (71), 133 (100). IR 
(KBr), ν/cm-1: 3088, 2956 (С-Н), 2836, 1600, 1508, 1484, 1284, 
1172, 752, 692.  
 
N-[(5Z)-4-(4-Nitrophenyl)-5H-1,2,3-dithiazol-5-ylidene]-N-
phenylamine (12c): (E)-1-(4-Nitrophenyl)ethan-1-one oxime 9f47 
(180 mg, 1 mmol) was treated according to general procedure C 
to afford compound 12c as orange crystals (85 mg,  27%): m.p. 
171-172 °C. Anal. Calcd. for C8H4N2O2S3 (%): C, 53.32; H, 2.88; 
N, 13.32; O, 10.15. Found (%): C, 53.48; H, 2.88; N, 13.32. 1H 
NMR (300 MHz, CDCl3) δ: 7.23 (3Н, m, Ph), 7.48 (2Н, m, Ph), 
8.31 (2Н, d, J = 8.3 Hz, Ar), 8.49 (2Н, d, J = 8.3 Hz, Ar). 13C NMR 
(75.5 MHz, CDCl3) δ: 124.2, 128.6, 135.3, 135.4, 131.0 (9 CH, Ar), 
143.5, 153.4, 157.9, 162.5, 164.0 (5 sp2 tertiary C). MS (EI, 70 eV), 
m/z (%): 315 (M+, 13), 167 (54). IR (KBr), ν/cm-1: 1612, 1600, 
1580, 1576, 1492, 1276, 1076, 832, 756, 696.37 
 
Ethyl (5Z)-5-(phenylimino)-5H-1,2,3-dithiazole-4-carboxylate 
(12d): Ethyl (E)-2-(hydroxyimino)propanoate 9g65 (131 mg, 1 
mmol) was treated according to general procedure C to afford 
compound 12d as a red oil (154 mg, 58%): Anal. Calcd. for 
C11H10N2O2S2 (%): C, 49.61; H, 3.78; N, 10.52. Found (%): C, 
49.88; H, 4.02; N, 10.42. 1H NMR (300 MHz, CDCl3) δ: 1.43 (3H, 
t, J = 7.3 Hz, CH3), 4.38 (2Н, q, J = 7.3 Hz, CH2), 7.16 (3Н, m, Ph), 
7,46 (2Н, m, Ph). 13C NMR (75.5 MHz, CDCl3) δ: 14.2 (CH3), 63.0 
(СН2), 119.3 (2 CH, Ph), 126.4 (CH), 129.8 (2 CH, Ph), 139.4, 
152.1, 153.3, 160.4 (4 sp2 tertiary C). MS (EI, 70 eV), m/z (%): 
266 (M+, 40), 167 (80). IR (KBr), ν/cm-1: 3076, 2960 (С-H), 2924, 
2852, 1744 (С=О), 1700 (С=О), 1584, 1540, 1484, 1368, 1216, 
1144, 740, 676.37 
 
Ethyl (Z)-2-cyano-2-(4-(4-fluorophenyl)-5H-1,2,3-dithiazol-5-
ylidene)acetate (13): Sulphur monochloride (0.32 mL, 4 mmol) 
and pyridine (0.48 mL, 6 mmol) were successively added 
dropwise to a solution of (E)-1-(4-fluorophenyl)ethan-1-one oxime 
(9c) (153 mg, 1 mmol) in dichloromethane (15 mL) at –7 °C under 
argon. The reaction mixture was kept at –2 °C for 20 min and a 
solution of ethyl 2-cyanoacetate (1.13 g, 10 mmol) in acetonitrile 
(10 mL) was added dropwise at –15 °C and the resulting mixture 
was stirred for 1 h. Pyridine (0.32 mL, 4 mmol) was added 
dropwise at –15 °C, the temperature steadily raised to room 
temperature and solvent evaporated under reduced pressure. 
The residue was purified by column chromatography (Silica gel 
Merck 60, light petroleum and then light petroleum-CH2Cl2 
mixtures) to afford compound 13 as orange crystals (49 mg, 16%): 
m.p. 188-193 °C. Anal. Calcd. for C13H9FN2O2S2 (%): C, 50.64; H, 
2.94; F, 6.16; N, 9.09. Found (%): С 50.49; Н 3.10; N 9.12. 1H 
NMR (300 MHz, CDCl3) δ: 1.38 (3H, t, J = 7.3 Hz, CH3), 4.37 (2Н, 
q, J = 7.3 Hz, СН2), 7.21 (2H, t, J 8.5, Ar), 7.46 (2H, m, Ar). 13C 
NMR (75.5 MHz, CDCl3) δ: 14.3 (CH3), 63.2 (CH2), 116.1 (2 CH), 
131.5 (2 CH), 90.3, 113.1, 128.6, 162.3, 163.1, 166.3, 167.5 (7 
sp2 C). MS (EI, 70 eV), m/z (%): 308 (M+, 62), 235 (100), 153 (22). 
IR (KBr), ν/cm-1: 2928 (C-H), 2204 (CN), 1664, 1520, 1444, 1280, 
1104, 824, 792, 700. 
 
2-Benzyl-4-phenyl-1,2,5-thiadiazole-3(2H)-thione (14) Benzyl 
amine (0.109 mL, 1 mmol) was added to a solution of 4-Phenyl-
5H-1,2,3-dithiazole-5-thione (10a) (0.106 mg, 0.5 mmol) in THF 
(4 mL) at room temperature. The reaction mixture was stirred for 
3 h at room temperature, the alkylammonium hydrogen sulphide 
was filtered off, and the solvent evaporated under reduced 
pressure. The residue was purified by column chromatography 
(Silica gel Merck 60, light petroleum, and then light 
petroleum/CH2Cl2 mixtures) afford compound 14 as a yellow 
crystalline solid (80 mg, 56%): m.p. 95-97 °C; Anal. Calcd for 
C15H12N2S2: C, 63.35; H, 4.25; N, 9.85; S, 22.55. Found (%): C, 
63.45; H, 4.39; N, 10.05; S, 22.68. 1H NMR (300 MHz, CDCl3) δ: 
5.31 (2H, s, CH2), 7.49 (8H, m, Ar), 8.42 (2H, m, Ar). 13C NMR 
(75.5 MHz, CDCl3) δ: 53.8 (CH2), 128.1 (2CH, Ar), 129.1 (2CH, 
Ar), 129.5 (2CH, Ar), 129.9 (2CH, Ar), 129.9 (CH, Ar), 130.5 (CH, 
Ar), 133.0 (sp2 C), 133.2 (sp2 C), 160.5 (sp2 C), 177.4 (C=S). MS 
(EI, 70 eV), m/z (%): (M+, 25), 251 (13). IR (KBr) ν/cm-1: 3064, 
2928 (C–H), 2852, 1496, 1456, 1428, 1344, 1332, 1292, 1208, 
1028, 848, 772, 756, 708, 696.59 
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